Drug Target Review

OCTOBER 17, 2024

While its involvement in the do-not-eat-me signal from cancer has inspired therapeutic development of this pathway for oncology, the function of the innate immune checkpoint we identified in 2009 1 extends to both innate and adaptive immune responses. 2009 Mar 5;323(5922):1722–5. The first patient has been dosed in the last quarter.

Immune Response 52

Immune Response Clinical Trials Trials Therapies 52

FDA Law Blog: Biosimilars

FEBRUARY 27, 2024

156, a patent may be extended only once (even if it would be eligible for extension on more than one occasion because it applies to several FDA-approved products), and only one patent may be extended for each regulatory review period. Another case of same-day (and same-time) FDA approvals! To that end, 35 U.S.C. § 156(c)(4)

FDA Approval 59

FDA Approval FDA Production Therapies 59

FDA Law Blog: Biosimilars

AUGUST 12, 2024

Plaintiffs performed the necessary studies on BRAVECTO and filed an NADA on April 8, 2014; FDA approved the NADA on May 15, 2014. s Motion for Summary Judgment finding that FDA failed to provide fair notice to plaintiffs of the need to submit an NCIE rather than an INAD to trigger the start of the testing phase.

FDA 59

FDA Regulations FDA Approval Drugs 59

The Pharma Data

NOVEMBER 10, 2020

FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (“PMX”). PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. ” About Spectral and Dialco. Spectral is a Phase III company seeking U.S.

Therapies 52

Therapies Nurses FDA FDA Approval 52

The Pharma Data

OCTOBER 21, 2020

CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is currently only approved in Canada. Related Articles: Cabenuva (cabotegravir and rilpivirine) FDA Approval History. About ViiV Healthcare. Such factors include, but are not limited to, those described under Item 3.D Source: GSK . Source link.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

Codon

MARCH 28, 2023

In 2009, the USC professor received millions from the Defense Advanced Research Projects Agency, or DARPA, to build a device that plugs into the brain and enhances memory recall. The first project, REMIND, began in 2009. View our database of DARPA neurotechnology projects online. “I am a brain, Watson.

Engineering 52

Engineering Research Science FDA Approval 52

The Pharma Data

MARCH 27, 2022

FDA-approved labeling for OLUMIANT includes a Boxed Warning for Serious Infections, Mortality, Malignancy, Major Adverse Cardiovascular Events, and Thrombosis. Marketing authorization for the treatment of hospitalized patients with COVID-19 has been granted for OLUMIANT in multiple countries. See the full Prescribing Information here.

Licensing 40

Licensing Licensing Disease FDA Approval 40

Broad Institute

MAY 21, 2025

In 2007, Sadelain and Rivire treated their first patient with leukemia, and in 2009, published details on how they manufactured personalized CAR T cells to treat patients with aggressive leukemia. Sadelain and Rivire also developed safe and reliable ways to produce these cells for use in patients.

Therapies 119

Therapies FDA Approval Engineering Immune Response 119

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. Following today’s FDA approval, the U.S.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

PLOS: DNA Science

OCTOBER 17, 2024

FDA approved a treatment for type 3 of the ultra-rare genetic disease September 20. The new drug is taken with miglustat , which FDA approved for use in NPD3 in 2009. The original approved was in 2003 to treat a type of Gaucher disease. Until today, there were no approved therapies in the US.

Disease 52

Disease FDA Approval Drugs Treatment 52

Drug Target Review

JUNE 21, 2023

Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. 2009 Nov 27;326(5957):1231-5. Why Clinical Trials Stop: The Role of Genetics. medRxiv; 2023. DOI: 10.1101/2023.02.07.23285407. Ochoa D, Karim M, Ghoussaini M, Hulcoop DG, McDonagh EM, Dunham I. Nat Rev Drug Discov. 2022 Aug;21(8):551. PMID: 35804044.

Disease 111

Disease Clinical Trials Therapies Science 111

The Pharma Data

OCTOBER 9, 2021

STELARA is the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, both of which play an important role in inflammation associated with immune-mediated diseases like PsA.

FDA Approval 52

FDA Approval Treatment FDA Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 9, 2021

FDA-approved labeling for OLUMIANT includes a Boxed Warning for Serious Infections, Malice, and Thrombosis. Marketing authorization for the treatment of rehabilitated cases with COVID-19 has been granted for OLUMIANT in multiple countries. See the full Prescribing Information then.

Treatment 52

Treatment FDA Approval Licensing Licensing 52

The Pharma Data

JUNE 24, 2021

Talazoparib is currently approved under the brand name TALZENNA ® for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Selection of patients for therapy is based on an FDA-approved companion diagnostic for TALZENNA.

Clinical Trials 52

Clinical Trials DNA Trials Treatment 52

The Pharma Data

APRIL 8, 2021

in the FDA-approved full Prescribing Information for additional information on risks associated with longer-term treatment with baricitinib. Additional information regarding baricitinib for its FDA-approved indication, including safety information, may be found in the full? Warnings and Precautions ?in

Hospitals 52

Hospitals FDA Approval Laboratories Treatment 52

The Pharma Data

OCTOBER 14, 2020

Risks and uncertainties related to these endeavors include, but are not limited to, obtaining FDA approval of NantKwest’s NK cells and MSC as well as other therapeutics and manufacturing challenges. 2009 Sep;16(9):673-82. Epub 2009 Feb 20. PMID: 23624851; PMCID: PMC3732790. iv Osada T, et al. Cancer Gene Ther.

Vaccine 40

Vaccine Trials FDA Clinical Trials 40

Agency IQ

JUNE 16, 2023

0910-AI26 September 2023 March 2023 Final Rule Stage Biologics License Applications and Master Files The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) deemed any biological product approved in a new drug application (NDA) to be a biologics license application (BLA) on March 23, 2020.

Regulations 40

Regulations FDA Science Production 40

Agency IQ

JUNE 2, 2023

In 2007, the FDA held a public workshop to hear from the public about the Medication Guides system; per the agency , “the public testified that the Medication Guides distribution processes needed improvement” and that it should be “shorter and easier to read.” After all, companies already have FDA-approved labels.

FDA 40

FDA FDA Approval Production Regulations 40

The Pharma Data

MAY 4, 2021

See Warnings and Precautions in the FDA-approved full Prescribing Information for additional information on risks associated with longer-term treatment with baricitinib. Olumiant was recently approved in Japan for the treatment of pneumonia associated with COVID-19 in hospitalized adult patients.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

MAY 4, 2021

See Warnings and Precautions in the FDA-approved full Prescribing Information for additional information on risks associated with longer-term treatment with baricitinib. Olumiant was recently approved in Japan for the treatment of pneumonia associated with COVID-19 in hospitalized adult patients.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

OCTOBER 29, 2020

“Alopecia areata is a challenging disease that currently has no FDA-approved treatment options, making it difficult for healthcare providers to best serve the needs of these patients,” said Brett King , MD, PhD associate professor of Dermatology at Yale School of Medicine.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

MARCH 4, 2021

There are currently no FDA-approved treatments for AA. OLUMIANT is a once-daily, oral JAK inhibitor approved in the U.S. FDA-approved labeling for Olumiant includes a Boxed Warning for Serious Infections, Malignancy, and Thrombosis. associate professor of Dermatology at Yale School of Medicine.

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

APRIL 6, 2021

OLUMIANT is a once-daily, oral JAK inhibitor approved in the U.S. FDA-approved labeling for Olumiant includes a Boxed Warning for Serious Infections, Malignancy, and Thrombosis. See the full Prescribing Information here.

Treatment 52

Treatment Drugs Clinical Trials Therapies 52

The Pharma Data

AUGUST 3, 2021

See Warnings and Precautions in the FDA-approved full Prescribing Information and Medication Guide for additional information on risks associated with longer-term treatment with baricitinib. It is also approved for the treatment of certain hospitalized patients with COVID-19 in Japan. Serious Side Effects.

Hospitals 52

Hospitals FDA FDA Approval Licensing 52

The Pharma Data

JULY 29, 2021

See Warnings and Precautions in the FDA-approved full Prescribing Information and Medication Guide for additional information on risks associated with longer-term treatment with baricitinib. It is also approved for the treatment of certain hospitalized patients with COVID-19 in Japan. Serious Side Effects.

Hospitals 52

Hospitals FDA Laboratories Treatment 52

New Drug Approvals

APRIL 27, 2025

3] It was patented in 1966 and approved for medical use in 1974. [6] 6] It was first approved in the US in 2004, and an extended release version was brought to market in 2007. It became generic in the EU in 2009, and the first extended-release generic was approved in the US in 2012. billion in 2004. [23] January 2011.

FDA Approval 57

FDA Approval FDA Pharmacokinetics Licensing 57

New Drug Approvals

APRIL 22, 2025

R*)))- FDA APPROVED sulopenem etzadroxil, probenecid, 10/25/2024, To treat uncomplicated urinary tract infections (uUTI) Drug Trial Snapshot Sulopenem ( CP-70,429 ) is a thiopenem antibiotic derivative from the penem family, which unlike most related drugs is orally active. . Ednie LM, Appelbaum PC (May 2009). 23.14.1497.31937.

FDA Approval 62

FDA Approval FDA Treatment Clinical Trials 62

Codon

JANUARY 26, 2025

The 2009 H1N1 “swine flu,” for example, emerged when human, avian, and swine strains mixed inside pigs. There is only one FDA-approved intranasal vaccine for any disease: the FluMist Quadrivalent flu vaccine, which uses weakened forms of viruses to trigger an immune response.

Vaccine 110

Vaccine Virus Immune Response Clinical Trials 110

Codon

FEBRUARY 23, 2025

Zidovudine showed promise against multiple HIV strains in cultured cells, and the Food and Drug Administration (FDA) approved it for human studies within five months. By 1987, the FDA licensed zidovudine after trials showed it increased survival rates. billion worth of doses — equivalent to 200,000 vaccines.

Clinical Trials 76

Clinical Trials Virus Vaccine DNA 76

Drug & Device Law

FEBRUARY 22, 2024

The history of litigation over a June 2009 to March 2012 shortage of a drug called Fabrazyme, which was at the time the only FDA-approved drug to treat a nasty thing called Fabry’s disease, helps to explain our view. We do not even need to call out the emphasis that plaintiff lawyers place on FDA approval when it suits them.

FDA Approval 52

FDA Approval Clinical Trials Trials Drugs 52

Drug & Device Law

FEBRUARY 15, 2024

As the DDL blog has previously reported , Michigan’s longstanding presumption of non-defectiveness applicable to FDA-approved drugs was recently repealed by the Michigan legislature in S.B. As this provision is newly applicable to FDA-approved products, it has not been tested by the courts on this issue. Saigh , 769 N.W.2d

Production 52

Production FDA Approval FDA Compliance 52

Drug & Device Law

NOVEMBER 2, 2023

Qualifying compounding pharmacies do not require FDA approval to sell compounded drugs. The defendant in Zyla is a qualifying compounding pharmacy that sells without FDA approval a compounded product containing the active ingredient found in the plaintiff manufacturer’s FDA-approved product. Mukasey , 536 F.3d

Compounding Pharmacies 59

Compounding Pharmacies Pharmacy FDA Approval FDA 59

Drug & Device Law

AUGUST 31, 2023

b)(2) not to make such a change without first obtaining FDA approval.” As construed by the court, the complaint alleged that the biologic approved by the FDA is defective as a matter of state law. Bartlett , 570 U.S. 2023 WL 5437356 at *7­. Note, however, the caveat. 2023 WL 5437356 at *7­. Courts are divided.

FDA Approval 59

FDA Approval FDA Production Pharmaceuticals 59

Drug & Device Law

JULY 24, 2023

at *6 (plaintiff “has documents and formularies reaching back to only 2009”). First, the class plaintiff got away with destruction of evidence. It preserved no records for nine of the eleven years of the class period.

Testimonials 52

Testimonials Pharmacy FDA Doctors 52

Drug & Device Law

MAY 11, 2023

488, 495 (2009), where it said expanding standing as proposed would “make a mockery” of Article III. It may very well fall to a rehearing en banc and/or the Supreme Court—each stocked with mostly “conservative” jurists—to restore some sanity to the mad world where FDA approvals can be wiped out retroactively more than two decades later.

FDA 59

FDA FDA Approval Research Drugs 59

Drug & Device Law

MAY 4, 2023

2015), finally gave appellate recognition to the preemption of design defect claims for FDA-approved branded prescription drugs. FDA approved the drug with its particular formulation and the manufacturer could not have changed the formulation on its own. As detailed here , the decision in Yates v. 3d 281 (6th Cir.

FDA Approval 64

FDA Approval FDA Regulations Production 64

Drug & Device Law

APRIL 14, 2023

The court denied the defendant’s motion, however, to the extent that the plaintiff’s claims were based on the defendant’s alleged failure to report adverse events associated with the device to the FDA. Contrary to the Second Circuit’s adherence to Erie conservatism in predicting state law, e.g. Runner v. New York Stock Exchange, Inc. ,

FDA 59

FDA Doctors Regulations FDA Approval 59